The leading cause of cancer death between genital malignancies is ovarian tumour. One of 100-120 female will die of the disease. Its peak incidence is the 4-7 decade. Besides the number of ovulations genetic environmental factors are involved into its pathogenesis. There are no specific symptoms in the early phase. Transabdominal and transvaginal ultrasounds are of great value showing not only the tumour shape itself, but also that of peritoneal metastases. Markers like Ca - 125, beta - HCG are of great importance, however, they do not have dominant role. The outcome is influenced by several components. ECOG - status of the patient, tumour size, histological grading, etc. are of predictive value and they play important role in planning complex therapy. Postoperative irradiation is of limited value in grade 1 - 2 tumours. Radiotherapy in advanced forms plays less important role due to specific side effect and constant leukopenia. Cyclophosphamide and cysplatin is the present gold standard, however, taxol - cysplatin could be a more fruitful combination. New drugs, like gemcitabine, irinothecan, high dose chemotherapy and other methods could lead to more effective treatment forms in the near future.
|Number of pages||6|
|Publication status||Published - Dec 1 1998|
ASJC Scopus subject areas